BJDX: Bluejay Diagnostics, Inc. Stock

by  •  • Comments Off on BJDX: Bluejay Diagnostics, Inc. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 0.98
Enterprise Value ($M) -3.33
Book Value ($M) 5.73
Book Value / Share 10.34
Price / Book 0.17
NCAV ($M) 3.97
NCAV / Share 7.17
Price / NCAV 0.25

Profitability (mra)
Return on Invested Capital (ROIC) -1.29
Return on Assets (ROA) -1.52
Return on Equity (ROE) -2.29

Liquidity (mrq)
Quick Ratio 6.05
Current Ratio 6.05

Balance Sheet (mrq) ($M)
Current Assets 4.90
Assets 6.66
Liabilities 0.93
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -7.17
Net Income -7.72
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -7.82
Cash from Investing -0.31
Cash from Financing 10.22

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A L1 Capital Global Opportunities Master Fund, Ltd.
11-14 13G Anson Funds Management LP 5.10
11-14 13G/A Armistice Capital, Llc 4.99 78.74

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRAN
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-06 15,376 56,452 27.24
2025-05-05 34,589 166,364 20.79
2025-05-02 30,067 203,167 14.80

(click for more detail)

Similar Companies
AXGN – Axogen, Inc. BBLG – Bone Biologics Corporation
BEAT – HeartBeam, Inc. BLFS – BioLife Solutions, Inc.
BSGM – BioSig Technologies, Inc.


Financial data and stock pages provided by
Fintel.io